Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
The study will assess the safety, pharmacokinetics (PK) and efficacy of different doses of
ARQ-151 cream (0.05% and 0.15%) vs placebo applied once a day for 28 days by adolescents and
adults with atopic dermatitis.